Introduction
To date, consensus on the methodology to evaluate new diagnostic tests is lacking [1] . Moreover, with rapid technical advances, especially in the field of imaging, diagnostic techniques undergoing evaluation may be already outdated before diagnostic and clinical values are established [2, 3] .
Similar to therapeutic research, a hierarchy can be discerned within diagnostic research [1,2,4e7] . The first step is the assessment of test characteristics of a new test. The next step is the evaluation of its added value [8] . The third step is the assessment of the effect on clinical outcome, and the final step comprises a cost-effectiveness analysis [7] . For evaluation of clinical outcome and cost-effectiveness of tests, randomized clinical trials (RCTs) are often not feasible.
We will shortly review each step of diagnostic research and discuss decision analysis as a useful alternative methodology for critical assessment of clinical value and efficient use of resources.
The hierarchy in diagnostic research
We will illustrate the different phases of diagnostic research following the example of carotid artery stenosis, a well-known risk factor for stroke. Carotid endarterectomy reduces this risk in selected patients [9, 10] . The standard technique for grading stenosis used to be digital subtraction angiography (DSA), an invasive imaging modality. Later on, magnetic resonance angiography (MRA) and duplex ultrasound (DUS) were introduced as noninvasive alternatives [11] .
Step 1: Test characteristics
Test characteristics of a diagnostic tool provide information on the ability to discriminate between the absence and the presence of disease. They are expressed in terms of sensitivity, specificity, predictive values, and likelihood ratios. Sensitivity and specificity are useful in selecting tests, whereas predictive values provide information on the probability of disease, given a certain test result [1] . Likelihood ratios characterize the change in the probability of disease
What is new?
In diagnostic research, decision models form a valuable alternative when randomized clinical trials (RCTs) are infeasible by integrating the best available evidence.
Decision-analytic models should be increasingly used to evaluate clinical outcome including costeffectiveness of fast developing diagnostic techniques.
after completing the test compared with the probability of disease before completing the test.
Test characteristics should be evaluated in a blinded cross-sectional study. Each test including a reference test needs to be performed in all study subjects to enable direct comparisons of the tests. Furthermore, the study participants ought to be representative of the target population [12, 13] . In diagnostic tools that require interpretation, intraand interobserver variability should also be assessed. In carotid artery stenosis, test characteristics of MRA and DUS have been established in a blinded cross-sectional study with DSA as the reference test [14] .
A limitation of assessing test characteristics is dichotomization of test results, whereas only a few tests yield just ''presence'' or ''absence'' of disease as test results. For continuous and ordinal test results, a threshold needs to be established to determine whether a result is positive or negative. Ideally, this positivity criterion should reflect the clinical impact of false-positive and false-negative results. In case of carotid stenosis, the consequences of false-positive results, such as complications of unnecessary treatment, should be weighed against the consequences of missing severe stenosis. Dichotomization generally leads to loss of information. To avoid this, likelihood ratios can be used. They represent the ratio between the likelihood of a particular test result in patients with a certain disease status and the likelihood of the same test result in patients without this disease status. In case of multiple test results, the likelihood ratio can be calculated for each test result. Subsequently, the probability of the presence of disease, given a certain test result, can be calculated starting from the probability of disease before the test result was known and the likelihood ratio of the pertaining test result [15, 16] .
A further limitation of test characteristics is the use of a ''gold'' standard to establish a ''true'' disease status. Within this framework, a new test can never outperform its reference test, which in daily practice has frequently happened. For example, computed tomography (CT) scanning was clearly better than skull radiography for assessing intracranial pathology.
Moreover, test characteristics are not constant, but are influenced by factors, such as prevalence of disease, disease severity, gender, age, and comorbidity. The higher the prevalence of disease, the higher the predictive value of a positive test result and the lower the predictive value of a negative test result. Apart from the predictive values, sensitivity and specificity may also be influenced by disease prevalence. However, the latter effect is indirect through prevalence varying with disease severity or disease spectrum. The probability of disease changes when information is obtained from the history, physical examination, and prior tests, because this information is used to select patients with a higher probability of disease for further diagnostic testing [17] . Within a specific selection of patients, the prevalence of disease and disease severity may be higher. In case of a more advanced stage of disease, the sensitivity will increase when abnormalities are easily detected. The relation between prevalence and clinical setting is illustrated by the comparison between a hospitalized bedridden patient who develops sudden dyspnea and hypoxia accompanied by an elevated level of d-dimers, and an otherwise healthy person who presents with acute dyspnea in an outpatient setting. Clearly, the first patient has a higher probability of pulmonary embolism than the second. Because the first patient was bedridden, more extensive pulmonary embolism could have been developed than in the second patient, which may increase the likelihood that embolism is detected on subsequent pulmonary CT angiography, thus increasing sensitivity. Conversely, in a screening setting, the prevalence of disease is low and disease stages are likely to be less advanced, which may increase the specificity. Hence, test characteristics can vary with the population in which the test is applied. The influence of other factors, such as age, sex, and comorbidity, on test characteristics can be evaluated by multivariate regression analysis [18, 19] .
Although seemingly straightforward, a considerable variation in study design in test research has been observed. To overcome inconsistent methodology and reporting on test research, the STARD initiative (Standards for Reporting of Diagnostic Accuracy) was launched [20] .
Step 2: Added value of a test
In clinical practice, tests are generally used in sequence. For each subsequent test, its added value must be considered. The added value in this phase of evaluation is expressed in terms of increase in proportion of patients correctly categorized as diseased or nondiseased, which is represented by an increased area under the receiver-operating characteristic (AUROC) curve.
Added value of a new test can be estimated using multivariate regression analysis [3, 8] .
In addition, a statistically significant increase in the AUROC curve does not necessarily represent clinical improvement, because this also depends on the positivity criterion. In patients with clinically suspected carotid artery stenosis, the added value of imaging will not inform us whether clinical outcome will improve in terms of strokes avoided. If MRA enables detecting smaller grade stenosis than DUS, more patients will have a positive test result. When patients with carotid artery stenosis benefit from treatment of severe stenosis only, which could already be accurately detected by DUS, detection of smaller grade stenosis by MRA will not improve outcome. Thus, added value in terms of a statistically significant increase in AUROC curve may not always have actual clinical value.
Step 3: Clinical outcome
The 7] .
RCTs in diagnostic research, however, have several limitations. Firstly, RCTs generally require a long follow-up before consequences of false-positive and false-negative test results become apparent. During this long period of follow-up, new diagnostic techniques may emerge, which may outdate the results of the trial before it is completed. Secondly, large groups of participants are often needed. When the new and the reference tests do not differ much in their ability to detect disease, only the limited subset of subjects with discordant test results carries relevant information. Dependent on the expected difference in disease course after diagnosis and ensuing treatment, the overall difference in outcome between the randomized groups may be further diluted. Therefore, a straightforward comparison of two diagnostic tests may already require many participants. Importantly, often more than two diagnostic tests require simultaneous evaluation. Additionally, various cutoff criteria, including multiple test results, the order of tests, and specific combinations of tests, will increase the number of diagnostic strategies to be evaluated. Representing all diagnostic strategies implies that the number of participants required increases exponentially. In the example of carotid stenosis, test characteristics of DUS, MRA, and DSA show little difference. An RCT should include ample participants to represent all relevant diagnostic strategies and to attain sufficiently large groups with discordant test results. Finally, a diagnostic RCT including an already established treatment strategy is inefficient. If outcome of treatment has already been established by therapeutic research, follow-up of treated patients would be redundant. In carotid stenosis, the effect on clinical outcome after carotid endarterectomy had already been assessed in therapeutic trials [9, 10] . Therefore, follow-up after treatment was deemed unnecessary for the evaluation of diagnostic strategies. An RCT would be a viable option only if the new diagnostic tool has consequences for treatment that has not been previously evaluated.
Decision-analytic models present an important alternative to an RCT [2, 5] . Through modeling, clinical outcome after application of a new test can be predicted by integrating the available evidence. A decision tree gives an overview of all diagnostic strategies with probabilities for each event. A decision tree will not suffice when events tend to recur or when events occur after a long and variable time span, such as in chronic diseases [21, 22] . For more complex diagnostic and disease processes, such as in carotid artery stenosis, Markov models are useful. These are typically based on probabilities of transitions between predefined health states for all possible scenarios. Timedependent risks and instantaneous risks for each scenario can be included. The distribution of patients among the different health states after a specified time span, for example, 1 year, is calculated. This can repeatedly be performed depending on the defined duration of follow-up. Uncertainty regarding the estimates of the input parameters of the model can be explored using Monte Carlo simulation. Through Monte Carlo simulation, multivariable sensitivity analysis is conducted to predict clinical outcome of a hypothetical group of subjects after a defined period of time, including uncertainty regarding the predicted outcome [22e24]. Decision-type models are flexible and can be designed to reflect an infinite number of diagnostic strategies. Furthermore, models can simulate a long follow-up period for a large group of subjects while recording all relevant outcomes and time frames simultaneously. Because there is no need to perform a lengthy RCT, the duration of uncertainty regarding the best diagnostic strategy is considerably shortened. Moreover, although decision models may appear complex and modeler driven, they do not obscure clinical evidence. All assumptions and estimates can be verified.
The level of decision uncertainty with regard to the appropriate diagnostic strategy is mostly reduced by an RCT. Decision modeling forms the only alternative where a proper RCT is unfeasible. Uncertainty remaining after a modeling study may be reduced by further research on the parameter that introduces most uncertainty. Whether investment of additional resources to reduce uncertainty is worthwhile can be formally assessed [25] .
There are some limitations to decision models. To create the model, sufficient information should be available. Furthermore, diagnostic processes may be too complex to summarize in a decision tree. In addition, decision models may never comprise all subtle associations and interactions of clinical reality. For instance, test characteristics are generally assumed to be constant and independent of other test results acquired previously. In reality, these previous test results can influence the interpretation of the subsequent test as being discussed before, but the actual change in test characteristics is rarely known. By sensitivity analysis, the influence of change in test characteristics on the eventual outcome can be assessed.
Step 4: Cost-effectiveness
Decision models can also keep track of resource use in relation to clinical outcome. The costs of the tests applied, the transitions, and events occurring can be integrated in the model. Subsequently, the incremental costs per additional unit of health, for example, extra costs per quality-adjusted life-year (QALY) gained, can be calculated for all diagnostic strategies. By comparing these results, the strategy with the best trade-off between costs and effects can be identified.
A study comparing 62 diagnostic strategies for carotid artery stenosis was performed. Using a Markov model, long-term outcome of the diagnostic work-up and following treatments in terms of life-years, QALYs, and costs were predicted and compared across strategies. DUS alone resulted in an optimal balance between costs and effects. The addition of MRA led to a slightly better outcome with a disproportionate increase in costs. Because of its complication risk, any strategy comprising DSA was proven inferior [26] .
This demonstrates that Markov modeling not only allows for assessment of cost-effectiveness, but also for evaluation of clinical outcome. Hence, this example covers steps 3 and 4.
Evaluation of decision models
Examples of validated decision-analytic models showed that the results of decision modeling were consistent with observed data from cohort follow-up studies [27e29]. For two of these studies, the input parameters of the Markov model originated from a cohort different from that with which the results were compared [27, 28] . Another study used the short-term follow-up data of an observational study cohort for a Markov model. The expected value of the model was compared with the long-term follow-up data of the same cohort and with data from the literature [29] .
A few aspects are important for the evaluation of Markov models. First, the model should reflect clinical reality in sufficient detail such that critical evaluation by expert peers remains possible. Furthermore, all model components, that is, the parameters describing each state transition, the health state value judgments, and cost estimates, need to be discussed in a multidisciplinary setting. Finally, because Markov models will be increasingly used, guidelines for its evaluation need to be developed [30, 31] .
We strongly recommend using decision models to evaluate diagnostic tests, provided reliable model parameters can be obtained, particularly, estimates of key variables. Notably, a reference standard is required to evaluate any diagnostic approach, because it remains essential for the diagnosis of any disease. This reference standard does not necessarily have to be a ''gold'' standard. Even though imperfection of a reference standard impairs perfect labeling of ''false''-positive and ''false''-negative test results, the impact of uncertainty of test characteristics on clinical outcome can be evaluated by Monte Carlo simulation. Finally, a standard treatment and pertaining outcome should be established. This can range from supportive treatment to causal treatment. For most of the diseases, a certain treatment can be recognized. Hence, we believe that, in most cases, a decision model has major advantages compared with diagnostic RCTs, because it saves time and resources, and allows cost-effectiveness analysis.
Conclusions
Evaluation of a diagnostic strategy requires a phased approach. For assessment of outcome in addition to test characteristics frequently, an RCT is neither feasible nor warranted. Decision-analytic models can integrate the best available evidence, including economic data, and should be part of the standard methodology in diagnostic research.
